NervGen Pharma Corp. announced a non-brokered private placement of 892,721 units at a price of CAD 2.60 per unit for gross proceeds of CAD 2,321,075 on November 29, 2021. Each unit issued in the private placement consisted of one common share and one-half of one common share purchase warrant. Each warrant is exercisable into one common share at a price of CAD 3.20 per common share until November 29, 2023. All of the securities issued pursuant to the private placement are subject to a four-month and one-day hold period in accordance with applicable Canadian securities laws. The transaction included participation from shareholders of the company including one director of the company William Radvak and 46 placees. In connection with the private placement and in accordance with the policies of the TSX Venture Exchange, the company paid certain finders a cash fee totaling CAD 20,430 to Canaccord Genuity Corp. and Raymond James Ltd. The TSX Venture Exchange has accepted for filing documentation with respect to the transaction. The company received CAD 822,655.7115 pursuant to Regulation D.